Many CF patients are starting to benefit from the recently FDA-approved drugs, including correctors that increase the plasma membrane abundance of mutant CFTR and potentiators that activate the corrected CFTR channel function [6]. This evidence concerns the gene CFTR and cystic fibrosis.